Back to top

Image: Bigstock

Endo International plc

Read MoreHide Full Article

Endo’s top line should continue to benefit from robust performance of Xiaflex, sterile injectables and alternative dosages. Its efforts to prioritize R&D projects bode well. Endo recently entered into an agreement to return rights to Belbuca to BioDelivery. Endo expects to realize cost savings, achieve higher efficiency and improve operational focus of its Branded segment. It plans to focus on Xiaflex in the approved indications and the cellulite development program. Endo will also be concentrating on its pain portfolio products. We are also pleased with Endo’s growth-by-acquisition strategy. However, both Branded and Generic segments are under pressure, which is concerning. Also, shares of Endo have underperformed that of the industry in the past one year. Continued pricing and competitive pressures remain major overhang on the shares. Estimates have come down ahead of the company’s fourth-quarter earnings results.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Endo International plc (ENDP) - free report >>

Published in